Targets and Products

Products

QVQ Research has developed single domain antibodies in three major disease areas: Cancer, Infectious diseases and Age related disease like Neuromuscular diseases and osteoarthritis and osteoporosis.

In the area of cancer imaging and therapy, QVQ has been involved in the CTMM Mammoth project, which aimed at developing new tools for optical imaging of breast tumors. This project delivered excellent VHHs against Her2 and CAIX, which are currently being produced under GMP conditions. QVQ also offers high affinity, well characterized VHHs directed against other cancer targets like EGFR, MET, uPAR, epCAM and Her3.

In the infectious disease area QVQ has a panel of VHH with a diversity of epitopes on HIV recognized by these VHH that can be used to investigate the various mechanisms of HIV-1 entrance and thereby help in the development of inhibition studies of the virus. High affinity well characterized VHH for p24, DC-SIGN and Hepatitis and many others are available.

In the Age related disease Osteoporosis, Osteoarthritis, QVQ works together with Twente University to develop VHH that can improve the repair of bone tissue by combining a targeting moiety to the extracellulair matrix combined with a capturing antibody that locally increases the level of endogenous growth factors which are beneficial for bone repair. Next to this, QVQ has VHH available against fibronectin, vitronectin, BMP6, 7,DKK  and a broad range of molecules related to other diseases that can be repaired by Tissue Repair.

Many diseases like neuromuscular and osteoporoses are related to ageing although genetic components in these diseases are also important.  In the neuromuscular area QVQ has been collaborating with LUMC in a FSHD foundation sponsored project to develop VHH that can improve the detection of FSHD muscular dystrophy. Next to this, QVQ has VHH available against vimentin, fibronectin, vitronectin, N-CAM and a broad range of molecules related to other muscular diseases. Moreover, QVQ has VHHs directed to neuro diseases like Alzheimer and Huntington

Check the list for your favorite molecule or contact sales@qvquality.com for more information on the possibilities of developing a high quality imaging agent for your molecule of interest

All products will be sold for research purposes only and will be custom made and functionalized for your application. Functionalization of these VHHs in order to generate high-end imaging agents include directional conjugation to IRDye800CW (LI-COR), Hylite dyes (Eurogentec), GFP, biotin, HRP, and chelators like NOTA, and DOTA.

A regular sample contains 250 μg of a (15kD) VHH. This equals ~17 nanomoles of antibody fragments, which equals ~2,5 mg conventional (150 kD) antibody to fulfill all research and imaging needs. Bulk quantities can be requested via sales@qvquality.com.

All Products

We are working hard to update our targets and products and move them forward in development. The status of our current development can be found here.

QVQ Targets may 2019

Phases of development

The development of VHH towards a high quality imaging agent involves 5 major steps. The products that are shown have an indication in which stage of development these products are. Below is described what the steps indicate:

fase-1Phase 1

Ready for monoclonal VHH selection. Immunizations of llamas were performed.


fase-2Phase 2

Ready for further characterization. Selections for monoclonal VHH were performed.

 


fase-3Phase 3

Ready for characterization in vitro. Lead molecules with high affinity have been identified.

 


fase-4Phase 4

Purified VHH available from E.coli production. VHH has been characterized in vitro.

 


Fase 5Phase 5

Ready for GMP production. Purified VHH (C-Direct) available from yeast production. VHH characterized in vivo.

 



fase-ster-150Star

Produced under GMP conditions. VHH characterized in vivo.

 


DevDevelopment

A stage or stages are in development. There can be one ore more stages in development at a time.